Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.73 (
urokinase-type plasminogen activator
)
10,685
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lucifer yellow (LY) accumulation was used to measure macrophage pinocytosis. The hematopoietic growth factors,
macrophage colony-stimulating factor
(
CSF-1
), granulocyte-macrophage CSF (GM-CSF), and interleukin 3, and the macrophage activators, lipopolysaccharide and zymosan, all stimulated LY uptake in both murine bone marrow-derived macrophages (BMMs) and resident peritoneal macrophages (RPMs) without affecting LY efflux. The stimulation of pinocytosis in the poorly cycling RPMs and in BMMs by nonmitogens dissociates stimulation of pinocytosis from subsequent DNA synthesis. Regulation of pinocytosis in BMMs appears to be independent of that of
urokinase-type plasminogen activator
expression. The increases in CSF-mediated BMM pinocytosis were not inhibited by pertussis toxin, by elevations in intracellular cAMP, or by glucocorticoids and were only partially inhibited by inhibitors of Na+/H+ antiport and Na+/K(+)-ATPase activities. Protein kinase C activation could be involved in regulating BMM pinocytosis because phorbol myristate acetate, oleoylacyglycerol, and exogenously added phospholipase C can all stimulate it. Ca2+ ionophores were inactive, whereas the Na+/H+ ionophore monensin potently inhibited BMM pinocytosis.
...
PMID:Regulation of pinocytosis in murine macrophages by colony-stimulating factors and other agents. 131 79
Macrophage colony-stimulating factor (
CSF-1
) increases the tissue invasive potential of the CSF-1 receptor-bearing lung carcinoma cell lines A549 and Calu-1 by increasing the number of endogenously bound
urokinase
-type plasminogen activators (u-PA)s on these cells.
CSF-1
, at concentrations which optimize invasion of A549 and Calu-1 cells into human amnion membranes (250 ng/ml), maximally augments the number of u-PA receptors occupied by endogenously produced
urokinase
. Preincubation of A549 and Calu-1 cells with the anti-u-PA monoclonal antibody MPW5UK (25 micrograms/ml) or with a 20- to 40-fold stoichiometric excess of fluid phase type 2 plasminogen activator inhibitor abrogates invasiveness, indicating that functionally active cell surface u-PA is essential for tissue invasion. In contrast, fluid phase type 1 plasminogen activator inhibitor (PAI-1, 5-15 units/ml) does not inhibit invasiveness unless preincubated with the amnion membranes. Inhibition of invasion by PAI-1 is abolished by presaturating the amnion membranes with antiitronectin monoclonal antibody (10 micrograms/ml) which prevents binding of PAI-1 to tissue-associated vitronectin. Binding of PAI-1 to tissue vitronectin is therefore a prerequisite for its inhibitory action. Thus, endogenously receptor-bound u-PA is the primary protease mediating
CSF-1
-induced tissue invasiveness of the lung carcinoma cell lines A549 and Calu-1.
...
PMID:Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell lines A549 and Calu-1. 137 33
The plasminogen activator (PA)/plasmin system has been implicated in the inflammation and connective tissue remodelling occurring in arthritic joints. PA activity is detected in cultures of human monocytes, synoviocytes and chondrocytes and can be regulated by a variety of cytokines found in diseased joints; PA inhibitors (PAI-1 and/or PAI-2) are also produced by these cells. We have shown that human monocytes can synthesize both
urokinase
-type PA (u-PA) and tissue-type PA (t-PA). One cytokine present in rheumatoid synovial fluids, granulocyte
macrophage colony stimulating factor
(GM-CSF), stimulates monocyte u-PA production; since this cytokine can also be produced by activated monocytes and other cell types in joints, than a "CSF network" can be produced leading to u-PA production. Another monocyte cytokine, interleukin 1, causes human synoviocytes to increase their u-PA expression, a response which can be dependent on the presence of endogenous cyclooxygenase products; this cytokine also causes human chondrocytes and cartilage tissue to produce increased u-PA and t-PA activity, i.e., under conditions during which cartilage is resorbed.
...
PMID:Regulation of plasminogen activator activity in arthritic joints. 190 74
The aim of this report is to review the role of
CSF-1
and its receptor in neoplasms of the breast and female reproductive tract. Expression and function of
CSF-1
and its receptor were studied in tumours of the human breast, ovary and endometrium.
CSF-1
and its receptor, initially implicated as essential to normal monocyte development and trophoblastic implantation, have been more recently shown to be expressed by carcinomas of the breast, ovary and endometrium where activation of the receptor by ligand produced either by the tumour cells or by stromal elements stimulates tumour cell invasion by a
urokinase
-dependent mechanism. Breast carcinomas express wild-type
CSF-1
receptors at levels comparable to those observed in trophoblast and monocytes. Ovarian and endometrial carcinomas express significantly lower levels of wild-type, functional CSF-1Rs while ovarian carcinomas also express unusual transcripts which diverge from the wild-type CSF-1R transcript in their 5' extracellular and other sequences. Tumour cell expression of CSF-1R is under the control of several steroid hormones (glucocorticoids and progestins) and tumour cell
CSF-1
expression appears to be regulated by other hormones, some of which are involved in normal lactogenic differentiation. In addition, tumour cells often produce
CSF-1
at such high levels that
CSF-1
spills into the extracellular fluid and circulation. Measurements of circulating levels of
CSF-1
have proved useful in patients with ovarian, endometrial and breast carcinoma patients both for disease detection and monitoring of response to breast carcinoma patients both for disease detection and monitoring of response to therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:CSF-1 and its receptor in ovarian, endometrial and breast cancer. 774 5
The mouse
urokinase-type plasminogen activator
(
uPA
) gene was used as a model
macrophage colony-stimulating factor
1 (
CSF-1
)-inducible gene to investigate
CSF-1
signalling pathways. Nuclear run-on analysis showed that induction of
uPA
mRNA by
CSF-1
and phorbol myristate acetate (PMA) was at the transcriptional level in bone marrow-derived macrophages.
CSF-1
and PMA synergized strongly in the induction of
uPA
mRNA, showing that at least some components of
CSF-1
action are mediated independently of protein kinase C. Promoter targets of
CSF-1
signalling were investigated with NIH 3T3 cells expressing the human CSF-1 receptor (c-fms).
uPA
mRNA was induced in these cells by treatment with
CSF-1
, and a PEA3/AP-1 element at -2.4 kb in the
uPA
promoter was involved in this response. Ets transcription factors can act through PEA3 sequences, and the involvement of Ets factors in the induction of
uPA
was confirmed by use of a dominant negative Ets-2 factor. Expression of the DNA binding domain of Ets-2 fused to the lacZ gene product prevented
CSF-1
-mediated induction of
uPA
mRNA in NIH 3T3 cells expressing the CSF-1 receptor. Examination of ets-2 mRNA expression in macrophages showed that it was also induced synergistically by
CSF-1
and PMA. In the macrophage cell line RAW264, the
uPA
PEA3/AP-1 element mediated a response to both PMA and cotransfected Ets-2.
uPA
promoter constructs were induced 60- to 130-fold by Ets-2 expression, and the recombinant Ets-2 DNA binding domain was able to bind to the
uPA
PEA3/AP-1 element. This work is consistent with a proposed pathway for
CSF-1
signalling involving sequential activation of fms, ras, and Ets factors.
...
PMID:Regulation of urokinase-type plasminogen activator gene transcription by macrophage colony-stimulating factor. 776 Aug 40
To address the role of ras signaling in monocytic phagocytes in vivo, the expression of two dominant suppressors of in vitro ras signaling pathways, the carboxyl-terminal region of the GTPase-activating protein (GAP-C) and the DNA binding domain of the transcription factor ets-2, were targeted to this cell compartment. A 5-kb portion of the human c-fms proximal promoter was shown to direct expression of the transgenes to the monocytic lineage. As a result of the GAP-C transgene expression, ras-GTP levels were reduced in mature peritoneal macrophages by 70%. The terminal differentiation of monocytes was altered, as evidence by the accumulation of atypical monocytic cells in the blood. Mature peritoneal macrophages exhibited changes in
colony-stimulating factor 1
-dependent survival and structure. Further, expression of the
colony-stimulating factor 1
-stimulated gene
urokinase plasminogen activator
was inhibited in peritoneal macrophages. The results indicate that ras action is critical in monocytic cells after these cells have lost the capacity to traverse the cell cycle.
...
PMID:Alterations in differentiation and behavior of monocytic phagocytes in transgenic mice that express dominant suppressors of ras signaling. 782 38
The
macrophage colony-stimulating factor
(
CSF-1
) is best known as a hematopoietic cytokine important to macrophage activation. Recently, the importance of
CSF-1
and its receptor (encoded by the c-fms proto-oncogene) in epithelial ovarian cancer has also been recognized, with overexpression of
CSF-1
denoting poor prognosis in ovarian cancer patients. During macrophage activation,
CSF-1
promotes
urokinase-type plasminogen activator
(
uPA
) activity; in macrophages and in malignant cells of lung, breast, colon, and prostatic origin,
uPA
activity is strongly correlated with the ability to invade and, in the malignant cells, to metastasize. While there is clear evidence of
CSF-1
and
uPA
expression in primary and metastatic ovarian cancer, the significance of their expression to invasion of these cells has not been explored. We find that all of our ovarian cancer cell lines which we have studied co-express
CSF-1
and
uPA
transcripts and protein. Urokinase expression in these ovarian cancer cell lines correlates with the degree of tumorigenicity in nude mice, with the most virulent tumor resulting from Hey cells, a strong expressor of
uPA
. We studied the invasion of these primary and established ovarian cancer cells through a Matrigel (reconstituted basement membrane matrix) barrier. The ability of ovarian cancer cells to invade is strongly correlated with endogenous
CSF-1
expression (Pearson's correlation, r = 0.91; P = 0.01). A total of 0.90 +/- 0.16% of Bix3 cells (very weak expressor of
CSF-1
) invaded through the barrier, in contrast to 6.95 +/- 0.75% of Hey cells (strong
CSF-1
expressor) and 10.44 +/- 2.33% of Bixler cells (the strongest
CSF-1
expressor). We studied the ability of two of the cell lines to invade human laminin and type IV collagen (Bix3, a weak invader of Matrigel, and Hey, a strong invader), to determine (a) whether our results on a Matrigel matrix may represent a relevant model for invasion in humans and (b) whether there is a potential confounding effect from the cytokines and proteases in Matrigel. On this human simple matrix, we confirm that Bix3 is a weakly invasive cell line (0.33 +/- 0.04% invasion) which contrasted to the strongly invasive Hey cell line (8.51 +/- 0.47%). Treatment of Bix3 cells with exogenous
CSF-1
stimulates percentage of invasion by 2-fold and results in a similar increase in the level of
uPA
transcripts and cellular associated
uPA
antigen. Furthermore, cell surface-bound
uPA
increased from 74% in the absence of
CSF-1
to 100% (fully saturated) in the presence of
CSF-1
.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase. 788 68
Macrophage colony-stimulating factor (
M-CSF
or
CSF-1
) and granulocyte-macrophage CSF (GM-CSF) have been shown to increase human monocyte
urokinase
-type plasminogen-activator (u-PA) activity with possible consequences for cell migration and tissue remodeling; because monocyte u-PA activity is likely to be controlled in part also by the PA inhibitors (PAIs) made by the cell, the effect of
M-CSF
and GM-CSF on human monocyte PAI-2 and PAI-1 synthesis was investigated. To this end, elutriation-purified human monocytes were treated in vitro with purified recombinant human
M-CSF
and GM-CSF, and PAI-2 and PAI-1 antigen and mRNA levels measured by specific enzyme-linked immunosorbent assays and Northern blot, respectively. Each CSF could enhance the protein and mRNA levels of PAI-2 and PAI-1 at similar concentrations for each product. This similar regulation of monocyte PAI expression in response to the CSFs contrasted with that found for the effects of lipopolysaccharide, transforming growth factor-beta and a glucocorticoid. Therefore, PAIs may be modulating the effects of the CSFs on monocyte u-PA activity at sites of inflammation and tissue remodeling.
...
PMID:Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human monocytes. 826 Jul
It is often assumed that macrophage-colony stimulating factor (M-CSF) or
CSF-1
, as well as granulocyte macrophage-CSF (GM-CSF), can induce inflammatory mediator production by monocytes/macrophages. We demonstrate with elutriation-purified human monocytes that, in contrast to lipopolysaccharide, recombinant human
CSF-1
does not induce secretion of prostaglandin E2, interleukin-6 (IL-6), IL-1 beta, or tumor necrosis factor alpha, as measured by immunoassay; however, increased
urokinase-type plasminogen activator
(
u-PA
) activity in cell lysates and mRNA was observed. Similar results were obtained when the monocytes were treated with recombinant human GM-CSF. Such increased
u-PA
expression may contribute to the function of
CSF-1
at sites of inflammation.
...
PMID:Effects of macrophage-colony stimulating factor on human monocytes: induction of expression of urokinase-type plasminogen activator, but not of secreted prostaglandin E2, interleukin-6, interleukin-1, or tumor necrosis factor-alpha. 831 54
Differentiation of monocytic precursors often results in adhesive properties thought to be important in migration. In this study, the influence of cytokines, known to induce macrophage differentiation, on the adhesiveness of the monocytic cell line U937 was examined in vitro. Despite development of a macrophage morphology, < 5% of cytokine-stimulated U937 cells were adherent at 24 h. Addition of 1-10 nM
urokinase-type plasminogen activator
(
uPA
) induced adherence in the presence of transforming growth factor type beta-1, 1,25-(OH)2 vitamin D3, granulocyte
macrophage colony-stimulating factor
, or tumor necrosis factor alpha.
uPA
-dependent adhesiveness was reversible after 24 h of stimulation with cytokines and
uPA
as adherence was prevented by the subsequent addition of anti-
uPA
antibodies. Adherence induced by diisopropylfluorophosphate-inactivated
uPA
was severalfold greater than that seen with active
uPA
. This difference was largely due to cell-surface turnover of active
uPA
complexed with plasminogen activator inhibitor (PAI). These data indicate that cytokines prime monocyte progenitors for
uPA
receptor-mediated signals leading to adherence, continued
uPA
receptor occupancy is required for adherence, and PAI decreases adherence by promoting clearance of
uPA
/PAI complexes. Thus the interaction of
uPA
and PAI at the cell surface, known to affect extracellular matrix proteolysis and hence myeloid cell migration, also regulates adhesion. The coordinated regulation of these two
uPA
functions by PAI may enhance the migratory potential of monocytic cells.
...
PMID:Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. 838 90
1
2
3
4
Next >>